eligibility_summary
Eligible: 18–70 with recurrent GBM and residual tumor after Tiantan surgery/biopsy, ≥4 wks since prior RT/temozolomide/bevacizumab with ≤G1 toxicity, KPS ≥70, life ≥8 wks, fit for Ommaya CSF shunt, consent, adequate labs (counts, liver/renal), SpO2 ≥95, HIV−, negative pregnancy test and contraception. Exclude: severe allergies, psych disease, recent trials/treatments, infection, major organ/autoimmune/immunosuppressed/neuro disease, prior gene therapy/transplant, chronic steroids, pregnant/lactating, investigator discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Autologous 4th‑generation “Tris‑CAR‑T” cells (genetically engineered T‑cell therapy) delivered locoregionally via Ommaya reservoir for recurrent glioblastoma. Mechanism of action: Patient T cells are lentivirally modified to express a dual‑target CAR recognizing CD44 and CD133 (inverse‑correlated antigens) to limit antigen escape and eliminate glioma/cancer stem‑like cells. The CAR incorporates a truncated IL‑7 receptor alpha intracellular module to enhance T‑cell survival, persistence, and activity. Targets and pathways: Tumor cells expressing CD44 (hyaluronan receptor, invasion/stemness) and CD133/PROM1 (glioma stem‑cell marker). T‑cell effector pathways engaged via CAR activation (CD3ζ/co‑stimulation) plus IL‑7R signaling. Locoregional intratumoral/intraventricular delivery aims for direct CSF/tumor exposure. Primary focus: safety and biodistribution.